Plasmepsin II (PM II) is an aspartic protease active in hemoglobin (Hb) degradation in the protozoan parasite Plasmodium falciparum. A fluorescence-quenched octapeptide substrate based on the initial hemoglobin cleavage site is recognized well by PM II. C-terminal extension of this peptide has little effect, but N-terminal extension results in higher maximal velocity and dramatic concentration-dependent substrate inhibition. This inhibition, but not the rate stimulation, depends on the presence of a DABCYL group on the peptide N terminus. Using sitedirected mutagenesis, we have identified PM II residues that interact with N-terminal amino acids of peptide substrates. The same residues influence degradation of Hb by PM II. Cathepsin E (CatE), a related mammalian aspartic protease, is also stimulated by N-terminally extended substrates. This suggests that distal substrate interactions as far out as P6 may be a general property of aspartic proteases and may be important in substrate and inhibitor recognition. Although PM II and CatE are similar in their ability to cleave Hb-based peptides and Hb ␣-chains, CatE is not able to degrade native Hb, which is a substrate for PM II. Based on these results, we propose that PM II may have the special feature of being a Hb denaturase.
1 degradation (4 -6). Additionally, Hb degradation may create space for the growing parasite and contribute to osmolar maintenance (7) . Thus, hemoglobinases are considered an important chemotherapeutic target.
Aspartic proteases may be especially important for the survival of the parasite because inhibitors specific for this class of enzymes kill parasites early in their erythrocytic life cycle (5, 8) . Three aspartic proteases, called plasmepsins (PMs), and one closely related protease (histo-aspartic protease) containing a histidine in place of an active site aspartate, reside in the food vacuole, the site of Hb degradation (9) . Each of the food vacuole PMs cleaves Hb in the ␣-chain between Phe-33 and Leu-34, (10 -12) . Cleavage at this site is speculated to lead to Hb denaturation and, thus, generation of additional protease-accessible sites.
To better characterize the molecular mechanism underlying Hb degradation by PMs, we studied the catalytic properties of PM II with peptide substrates and Hb. Using fluorogenic peptide substrates, we discovered that PM II is subject to dramatic substrate inhibition. In addition, peptides extending far into unprimed subsites stimulate protease activity. Neither substrate inhibition nor rate enhancement is unique to PM II, but both are also present in distant relatives and may be common features of aspartic protease catalysis. The ability to degrade native Hb, on the other hand, is not shared by relatives of PM, as CatE cleaves peptides based on the primary Hb cleavage site well but does not act on Hb.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification-Mature PM II (m-PM II) was generated by amplifying a construct encoding the proform of PM II (13) with the primers 5Ј-GCCATGGGTAGTTCAAATGAT-3Ј and 5Ј-CCAA-CAATTGGATCTACTGAA-3Ј. The PCR product was subcloned into pCR4, its sequence was confirmed, and it was digested with XbaI and MunI. The fragment was subcloned into an expression construct containing the C-terminal portion of PM II in the pET-3d vector. A construct containing 46 amino acids of the pro-domain (p77-p122) was amplified with the primers 5Ј-CCATATGTCCGAACATTTAACTATT-3Ј and 5Ј-GGATCCCTAATAATTTGTTTTAGTAAG-3Ј and, using the NdeI and BamHI sites, subcloned as a C-terminal glutathione S-transferase fusion protein into a pGEX expression vector. The proform-PM II construct contains an alteration in codon 238, with a change from Lys to Arg (13) . This conservative change does not affect peptide cleavage kinetics (data not shown). m-PM II mutant constructs were prepared using QuikChange with the primers (complement primers are not listed) 5Ј-GATGTTATCAGATGCCCATTCTTACCTAAATATGTAACTCTTTGT-AACAACAGAAAATT-3Ј (for m-F244K), 5Ј-ATGGGTTCAGAGTCCCA-TTCTGACCTGAATATGTAACTCTTTGTAACAACAGCAAAT-3Ј (for m-F244E), 5Ј-GTTGCAGAATTTAGATGTTATCAAAGTCCCATTCTT-ACCTTTCTAT-3Ј (for m-R238K), and 5Ј-TTAGATGTTATCAGAGTCC-CATTACCTTTCTATGTAACTCTTTGTACC-3Ј (for the deletion of Phe-241, m-d241). Expression of recombinant proteins was in Escherichia coli BL21(DE3) cells with 200 M isopropyl 1-thio-␤-D-galactopyranoside at 37°C for 4 -6 h in TB media (Qbiogene, Carlsbad, CA). After cell lysis by sonication, inclusion bodies were resuspended in buffer A (20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 150 mM NaCl) and washed 2 times each in buffer B (20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100) and buffer C (20 mM Tris-HCl, pH 8.5, 1 mM EDTA). Inclusion bodies were solubilized in buffer D (6 M urea, 20 mM Tris-HCl, pH 8.5, 1 mM EDTA) and applied to a heparin-Sepharose FF column equilibrated in buffer D. The proteins were collected in the flow-through and applied to a Mono Q 10/10 column equilibrated in buffer D. Proteins * This work was supported by National Institutes of Health Grant AI47798. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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were eluted from the Mono Q column with a linear gradient of 0 -1 M NaCl. Refolding was achieved by rapid 20 -30-fold dilution into buffer E (20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 10% glycerol) at room temperature and stirring for at least 14 h. To autoactivate the proform of PM II, sodium citrate, pH 4.7, at a final concentration of 0.1 M was added. The activated enzyme was then dialyzed into buffer E. Proteins were concentrated on a Mono Q 10/10 column, preequilibrated in buffer E, and eluted with a linear gradient of 0 -1 M NaCl. Final purification and removal of aggregates were performed with two gel filtrations on Superdex 75. Gel filtration 1 was carried out in buffer F (20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 10% glycerol, 0.25 M NaCl) on proteins that had been treated with 5 mM dithiothreitol. Gel filtration 2 was done in buffer G (20 mM MES, pH 6.0, 0.25 M NaCl). To prevent autolysis proteins were stored in buffer G containing 50 mM Tris-HCl, pH 8.5, at 4°C. To estimate the molecular masses of proteins, the Superdex 75 column was calibrated with low molecular weight standards in buffer G.
Enzyme Kinetics-Kinetic assays were performed with internally quenched fluorescent peptide substrates in real time using a Cary Eclipse fluorimeter (Varian) with excitation at 336 nm (slit width 5 nm) and emission at 490 nm (slit width 10 nm). The appearance of cleavage products was measured at 37°C for 40 -200s. Progress curves were followed to verify that linear initial rates were being measured, and different enzyme concentrations were used to ensure that activity increased linearly with increasing enzyme. Sequences of synthetic peptides were based on the primary site of cleavage within Hb, and numbering of the peptides corresponds to the residues within the ␣-chain of Hb. The sequences of synthetic peptides were as follows: 3037a, DAB-CYL-GABA-ERMFLSFP-EDANS; 2837a, DABCYL-GABA-ALERM-FLSFP-EDANS; 3037b, EDANS-CO-CH 2 -CH 2 -CO-ERMFLSFP-diaminopimelate-(DABCYL)OH; 2837b, EDANS-CO-CH 2 -CH 2 -CO-ALERMFLSFP-diaminopimelate-(DABCYL)OH. Peptides varying in length and/or identity of the residue at position 28 ( Figs. 2 and 3 ) contained N-terminal DABCYL with a GABA linker and C-terminal EDANS groups. Assays were performed in 0.1 M sodium acetate, pH 5.0, containing 10% glycerol (for peptides 3037b and 2837b) or 20% glycerol for all peptides containing N-terminal DABCYL groups. All peptides were determined to be Ն95% pure. They were dissolved in Me 2 SO, and a constant 2% Me 2 SO was used in the assays. Protease concentrations ranged between 0.5 and 3 nM. Catalytic parameters were determined only for substrates that were free of substrate inhibition. Averages of three to four measurements were used at each substrate concentration. K m and V max values were calculated by direct fitting of initial rates using the Michaelis-Menten equation and Kaleidograph software. Concentrations of enzymes were determined by active-site titration with pepstatin, and the k cat was calculated from k cat ϭ V max /[E] (14) . For all substrates displaying substrate inhibition, rates were measured for equal time periods. In these cases, the reported rates may not represent initial rates, but they are consistent throughout the experiment. Because substrate inhibition depended on protein concentration, the same concentration of PM II was used throughout. Fluorescence units were converted to molarity by measuring fluorescence intensities of complete digests at three peptide concentrations for each peptide.
Mapping of Cleavage Sites by Mass Spectrometry-Peptides 3037b and 2837b were dissolved in 30% acetonitrile, 0.01% trifluoroacetic acid and diluted to a concentration of 1 M for use. Digests were set up at pH 5.0 for 30 min to 4 h with either PM II, CatE, cathepsin D (CatD), or pepsin in 0.1 M ammonium acetate. Digested peptides were purified using ZipTips (C 18 matrix) and prepared for matrix-assisted laser desorption ionization mass spectroscopy using ␣-cyano-4-hydroxycinnamic acid as the matrix. Spectra were acquired on an Applied Bioscience 4700 Explorer Proteomics Analyzer in positive ion mode using the reflector. Sequence information was obtained using peptide fragmentation in tandem mass spectroscopy mode. For 3037b, a product with a mass of 930.4 was assigned to the N-terminal peptide in the cleavage reaction Phe-33-Leu-34, whereas the same cleavage resulted in a mass of 1114.5 with the 2837b peptide. A product with a mass of 967.4 from the parent 2837b peptide was mapped to the M32-F33 cleavage site.
Hemoglobin Degradation-Purified Hb and ␣-chains were gifts of the laboratory of Gary Ackers (Washington University School of Medicine, St. Louis, MO). The chains of Hb were isolated from one another with p-mercuribenzoate (15) . Purified ␣-chains contain heme but are not folded as tightly as native Hb (16) . Degradation experiments were performed by incubation at 37°C for 30 min to 18 h in 0.1 M sodium acetate, pH 5.0. Reactions were stopped by 2-fold dilution into SDS-PAGE-loading buffer and boiling for 3 min. Hb concentrations were estimated by densitometry using ImageJ software. Typical substrate concentrations were 0.2-10 M heme, and protease concentrations were 0.1-0.3 M. The stability of PM II mutants in the reaction mixtures was tested with fluorogenic peptides, and they were not different from the wild-type protease.
Reagents-Synthetic peptides were obtained from Anaspec (San Jose, CA). High performance liquid chromatography columns and gel filtration standards were from Amersham Biosciences. Pepstatin A and isopropyl 1-thio-␤-D-galactopyranoside were from Roche Applied Science. CatD (bovine), CatE (mouse recombinant), pepsin (porcine), and pET-3d were from EMD Biosciences (San Diego, CA). QuikChange mutagenesis kit was from Stratagene (La Jolla, CA), and the pCR4 vector was from Invitrogen. All other reagents were from Sigma.
RESULTS

Preparation of Recombinant Mature
Plasmepsin II-In the parasite, PM II is translated as an inactive zymogen containing a 124-amino acid-long N-terminal pro-sequence that has a membrane-spanning domain. Within the food vacuole the pro-sequence is removed by a calpain-like maturase, and native PM II is released (17) . In vitro, a PM II construct with a partial prosequence that is missing the transmembrane domain (N terminus at M70p) efficiently inhibits activity by stabilizing an open and catalytically incompetent conformation of the protease active site (18) . At acidic pH, this partial pro-PM II auto-activates to form auto-PM II containing 14 N-terminal amino acids that are not present in mature, native PM II (Fig. 1A) . Auto-PM II and native PM II have been shown to exhibit similar kinetic parameters with a synthetic peptide substrate (13) .
We sought to establish an expression system that bypasses the need for auto-activation. PM II expressed well from a pET3d construct that contained G124p after an initiator Met (Fig. 1A) , and inclusion bodies of the protein (referred to as mature or m-PM II) were purified. We thought that the pro- domain of PM II might be required for proper folding of the protease and hoped that providing this domain in trans would suffice. We prepared and purified a soluble glutathione Stransferase fusion protein containing residues p77-p122 of the pro-domain and added this glutathione S-transferase-pro-PM II at a molar ratio of 1:1 to m-PM II during refolding. As a control reaction m-PM II was prepared without the addition of glutathione S-transferase-pro-PM II. To judge the success of refolding, we measured the protease activity of both fractions and determined that it was equal (data not shown), indicating that in vitro, the residues encoding m-PM II are sufficient for proper folding. Consequently, m-PM II was purified and refolded similarly to auto-PM II (Fig. 1B) . Gel filtration gave an estimated M r of 37,400 for auto-PM II and an M r of 36,300 for m-PM II, compared with calculated M r values of 38,200 for auto-PM II and 37,000 for m-PM II (data not shown), and suggested that both proteins were monomeric under the conditions used. The yield of purified inclusion bodies was ϳ2-fold higher, and that of the refolded, active protein was up to 3-fold higher with m-PM II compared with auto-PM II. Using a fluorescence-quenched octapeptide (3037b), auto-PM II and m-PM II showed similar kinetic parameters (Table I) .
N-terminally Extended Substrate Peptides Enhance Plasmepsin II Activity-In attempting to model peptide substrates of PM II in the enzyme active site (co-crystal of PM II with inhibitors; Protein Data Bank codes 1SME, 1LF2, and 1LEE) (19, 20) , we observed that only a small portion of the active site is solvent-accessible. Consequently, PЈ residues could be accommodated, but extended P residues clashed with the protein. To investigate whether lengthening peptides N-terminally might have an effect on catalysis, we synthesized a series of peptides based on the sequence of the primary cleavage site within Hb. Both P and PЈ were extended beyond the original octapeptide (ERMFLSFP) (13) , and rates of peptide cleavage were measured (Fig. 2, A and B) .
As illustrated in Fig. 2A , an extension of two N-terminal amino acids was critical for maximal rate enhancement. Some, but not all of the P-extended peptides, showed strong substrate inhibition. Substrate inhibition without rate stimulation was observed in the nonapeptide P5-P4Ј, whereas the decapeptide P6-P4Ј exhibited rate enhancement as well as substrate inhibition. This suggested that rate enhancement and substrate inhibition are separate phenomena. Peptides that extended beyond the P6 position did not lead to additional rate stimulation. Peptides with a negatively charged N-terminal amino acids (P4-P4Ј, P4-P6Ј, P7-P4Ј) showed attenuation of substrate inhibition. Extending peptides beyond P4Ј did not result in either rate stimulation or substrate inhibition (Fig. 2B) . Instead, a modest rate decrease for all C-terminally extended peptides was observed. The origin of this rate decrease is unclear. Importantly, C-terminal extension of substrates did not inhibit the rate enhancement of the N-terminal extensions.
Thus, rate stimulation is determined by distal P-sites, particularly by P6.
Because the substrates were based on the sequence of Hb, extending the peptides not only changed their length but also FIG. 2 . N-terminally extended substrates stimulate plasmepsin II peptide cleavage. Cleavage rates of substrates (0.1-3 M) by 1.5 nM m-PM II in 0.1 M sodium acetate, pH 5.0, 20% glycerol. m-PM II was preincubated for 1 min in the assay buffer at 37°C, and reaction was started by the addition of substrate. The increase in fluorescence of the internally quenched substrates was followed for 100 s. A, extending the peptide N-terminally results in rate enhancement and strong substrate inhibition. Peptide sequences are shown in colored letters and are based on the primary cleavage site within hemoglobin. The sites of cleavage are marked by a dash. The octapeptide P4-P4Ј (dark blue) has little substrate inhibition; the nonapeptide P5-P4Ј (orange) has strong substrate inhibition; the decapeptide P6-P4Ј (magenta) has rate enhancement as well as substrate inhibition. No additional rate stimulation is observed by extending peptides beyond P6. B, increasing substrates C-terminally does not stimulate plasmepsin activity. Extending the octapeptide P4-P4Ј (dark blue) to the decapeptide P4-P6Ј (purple) does not result in rate enhancement or substrate inhibition. Extending P4-P6Ј N-terminally to P6-P6Ј (red) stimulates the peptide cleavage. their character. To analyze the contribution of amino acid side chains in detail, we synthesized a series of modified P6-P4Ј substrates in which the P6 residue was changed, whereas all other amino acids remained constant. As illustrated in Fig. 3A , side chains contributed to substrate inhibition and rate enhancement. Truncation of the P6 side chain by altering the residue from Ala to Gly resulted in a peptide with characteristics similar to the P5-P4Ј peptide. Replacing P6 with Ser, on the other hand, had little effect. Bulky side chains enhanced substrate inhibition (Fig. 3B) , with the most bulky and hydrophobic peptide (P6 ϭ Trp) being the most potent inhibitor. Aspartate at P6 released substrate inhibition (Fig. 3C) . Interestingly, an acidic peptide with a longer side chain (P6 ϭ Glu), showed rate enhancement beyond that observed with the ALERMF-LSFP peptide. This additional stimulation of the catalysis may result from the longer aliphatic side chain of the glutamate. Basic side chains at P6 had substrate inhibition similar to the ALERMF-LSFP peptide, whereas the extent of rate enhancement was variable and possibly depended on the hydrophobicity and/or orientation of the long side chains (Fig. 3D) .
To investigate whether the reduction in the rate of product generation at high substrate concentration was due to substrate or product inhibition, we tested whether product peptides could act as inhibitors. Neither the unmodified P1Ј-P4Ј peptide nor unmodified P-peptides of different length or Ppeptides containing an N-terminal DABCYL inhibited substrate cleavage under any of the tested conditions.
We examined whether the N-terminal DABCYL moiety of the synthetic peptides contributes to substrate inhibition by synthesizing a P4-P4Ј octapeptide and a P6-P4Ј decapeptide with an N-terminal EDANS and a C-terminal DABCYL group (peptides 3037b and 2837b). These modified substrates showed no substrate inhibition up to a concentration of 10 M with the octapeptide and only minimal substrate inhibition with the decapeptide (Fig. 4B) . The rate stimulation observed previously with the N-terminally extended substrates, however, was still present (Fig. 4 and Table I ). This confirmed that rate enhancement and substrate inhibition are independent phenomena and that distal P sites are critical for the stimulation of catalysis. The order of magnitude increase in catalytic efficiency with the longer peptide could be attributed to both better initial binding (decreased K m ) and better turnover (higher k cat ).
Localization of Distal S Sites-To determine which region of PM II interacts with the extended P-sites, we examined the PM II-pepstatin co-crystal structure and introduced a number of site-directed mutations. A loop (residues 240 -243 and neighboring amino acids) was of particular interest, since it is highly conserved among PMs and is stabilized by inhibitor binding (see "Discussion"). Replacing the wild-type Phe-244 with Glu or Lys resulted in m-PM II mutant proteins that had reduced catalytic efficiencies with either peptide (Table I) . Stimulation by the P-extended peptide was attenuated in the mutant enzymes. However, the reduced catalytic efficiencies of the two mutants were due to different mechanisms; m-F244E had a reduced k cat , whereas m-F244K had an increased K m . Replacing Phe-244 with Ala did not alter the kinetic parameters FIG. 3 . Side chains at P6 contribute to substrate inhibition and rate enhancement. m-PM II was prepared and rates were analyzed as in Fig. 2 . A, side chains contribute to substrate inhibition. Altering P6 in the decapeptide from Ala (magenta) to Gly (green) results in a peptide whose properties resemble the P5-P4Ј nonapeptide (orange). Changing Ala to the small polar Ser side chain (blue) does not significantly alter the peptide cleavage characteristics. B, bulky side chains enhance substrate inhibition. Changing P6 from Ala to larger hydrophobic groups gives more substantial substrate inhibition. Altering Ala to Trp (dark red) results in a peptide with extreme substrate inhibition. C, Asp at P6 eliminates substrate inhibition (green), whereas the peptide with the longer E side chain (blue) shows substrate inhibition and rate enhancement. D, basic side chains either behave like the 2837a peptide (Arg, green) or decrease the rate enhancement (Lys, blue). Positive charges located at the end of long side chains at P6 may not influence the peptides. Instead, the aliphatic character of the side chains may determine cleavage characteristics.
significantly. This suggests that the Phe-244 side chain does not participate in specific interactions with the peptide but that it is important for the proper formation of the structure and/or flexibility of the extended active site of the enzyme. A deletion of Phe-241 (m-d241) was similar to the m-F244E construct in that primarily the k cat was affected (Table I) .
Degradation of Hemoglobin by Wild-type and Mutant Plasmepsins-To see whether distal S-sites are only important for peptide cleavage or for protein cleavage as well, we studied the ability of PMs to degrade Hb. As shown in Table II , m-F244E and m-d241 had reduced Hb-cleavage ability, whereas m-F244K and m-F244A degraded Hb as well as the wild-type protein.
In the peptide kinetic analysis, m-F244E and m-d241 showed decreased k cat values (Table I) . For m-F244E we titrated the concentration of Hb in the assay, and the mutant activity differed from that of wild type only at saturating Hb concentrations above 1 M (data not shown), thereby demonstrating a k cat effect on protein as well as peptide.
Distal Unprimed Sites Are Important Determinants of Aspartic Protease Catalytic Efficiency-We wondered whether the rate stimulation with increased N-terminal peptide length was unique to PM II or a general feature of aspartic proteases and studied the catalytic properties of mammalian enzymes related to PM II (CatD, CatE, and pepsin). With the exception of pepsin all enzymes exhibited a rate enhancement. Substrate inhibition with peptides containing an N-terminal DABCYL was observed with CatD but not with CatE or pepsin (data not shown). Rate enhancement could either be a consequence of increased binding interactions as seen in PM II or the result from additional cleavage sites available in the longer substrate. To distinguish these possibilities, we used mass spectrometry and analyzed peptide fragments after protein digestion. Of the enzymes studied, PM II and CatE cleaved both 3037b and 2837b at Phe-33-Leu-34. CatD cleaved 3037b at Phe-33-Leu-34 and 2837b at Met-32-Phe-33 as well as at Phe-33-Leu-34. Pepsin had multiple cleavage sites for both peptides. The presence of multiple peptide cleavage sites complicated the interpretation of the observed catalytic stimulation, and we were, therefore, able to correlate substrate length with rate enhancement only for PM II and CatE. As illustrated in Table I , CatE showed an increase in catalytic efficiency with the longer peptide similar in magnitude to that of PM II. The stimulation of CatE was predominately due to increased k cat . Based on these observations we propose that interactions with distal substrate sites may be a common feature of aspartic proteases. Degradation of Hemoglobin and Hemoglobin ␣-Chains by Plasmepsin II and Cathepsin E-PM II and CatE differed in their ability to cleave native Hb. As shown in Fig. 5A , PM II could cleave Hb well, and after a 4 -6-h incubation, most Hb was degraded. CatE, on the other hand, minimally degraded Hb. However, when we used purified ␣-chains rather than Hb as the substrate, CatE was not nearly as impaired and cleaved the protein at ϳ30% that of the rate of PM II (Fig. 5B) . ␣-Chains are prepared by disrupting the Hb tetramer interactions and are not folded as tightly as native hemoglobin (16) . Thus, CatE could cleave peptides and loosely folded Hb ␣-chain but not native Hb, whereas PM II acted on all three substrates.
DISCUSSION
PMs initiate Hb degradation by cleaving the Phe-33-Leu-34 bond in the B-helix of the ␣-chain of Hb (10) . This peptide bond is inaccessible in native Hb, and proteolysis at this position is thought to lead to denaturation of Hb and exposure of additional cleavage sites to PMs and other downstream proteases such as falcipain-2 (21, 22) , falcilysin (23, 24) , and dipeptidyl-aminopeptidase I (25) . Our study supports the idea that PMs are unique among aspartic proteases in their ability to cleave native Hb well. Whereas CatE cleaves a Hb-based peptide and acts on the ␣-chains of Hb, it is almost completely inactive against native Hb. This observation suggests that the ability of PM II to cleave Phe-33-Leu-34 is not simply a consequence of stochastic unfolding of the ␣-chain B-helix. PM II appears to have a special ability to recognize and/or unwind the Hb molecule.
The loop connecting strands ␤6 and ␤7 in the C-terminal ␤-barrel domain of PM II (amino acids 240 -243 and neighboring residues) may be of critical importance. This region is highly conserved in all PMs (26) and is different and variable in other aspartic proteases (27) . It is the most highly ordered structural element of PM II when the active site is occupied but is invisible in the structure without inhibitor (28), indicating great flexibility. A survey of aspartic protease structures suggests that the degree of order of the corresponding loop region is not influenced by the active site occupancy except in the PMs. We show that mutating Phe-244 to Glu or deleting Phe-241 results in a lower k cat for peptide cleavage, a blunted rate enhancement for extended peptides, and impaired Hb cleavage. Because k cat relates to peptide bond cleavage and product release rather than the initial binding, this catalytic property may be especially important for cleaving protein substrates.
To approach the question of specificity of PM II, a series of chromogenic substrates with variations in the P4, P3, P2, P2Ј, and P3Ј positions has previously been analyzed (29) . The preferences at the primed positions have been characterized in detail with a random decamer peptide library, and it was shown that Leu and Ser are preferred at P1Ј and P2Ј, respectively, whereas there was little specificity at other positions (30) . The availability of related sequences has been beneficial to elucidate the substrate specificity of PM II. Studies investigating the kinetic parameters and inhibition profiles of P. falciparum PM I, PM IV, and histo-aspartic protease and of PMs from different malaria species illustrate that although the differences in the active sites are subtle, they may be exploited to lead to specific inhibitors (31) (32) (33) (34) . Much work has been done to characterize the subsite preferences of CatD (35, 36) , and the specificities of pepsin, CatE, and rhizopuspepsin have been systematically probed (37) . Here we describe how extending peptide substrates to the P6 position results in an increase in the catalytic efficiency not only for PM II but also for CatE. The lower K m with the decapeptide reflects better binding to the active site, and the increased k cat suggests that subsite occupancy may assist in the productive orientation of the bond to be cleaved. Such increases in k cat with longer peptides have been described as a common mechanism in protease catalysis (38) and are characterized in detail for aspartic proteases (39, 40) . Although our study describes the importance of hydrophobic moieties at N-terminal subsites for PM II and CatE, charge- charge interactions have been shown to participate in the substrate recognition of chymosin. Increasing the length of the chymosin substrate -casein from P5 to P6 results in a 3.5-fold decrease of the k cat (41) . Two anion binding exosites have been mapped in detail for the trypsin-like serine protease thrombin (42, 43) . Both exosites are of critical importance for the function of thrombin; glycosaminoglycan-bound serpins locate to exosite II, whereas fibrin and the inhibitor hirudin are tethered to exosite I (43, 44) . Thus, extended protein subsites can contribute to protease function and specificity.
The characterization of the mutant peptide substrates described here may lead to the development of new inhibitors. Several, but not all of the proteases examined were subject to strong substrate inhibition when peptides were modified by hydrophobic N-terminal groups such as DABCYL. The binding site likely involves a hydrophobic patch on the protein surface that is present in PM II and CatD but absent in CatE. We believe that careful mapping of the site that participates in substrate inhibition may allow for the development of specific inhibitors. We are intrigued by the possibility that PMs have unfoldase activity and are pursuing the mechanism by which native Hb is cleaved.
